Pre-clinical evaluation of effects of acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: PET study in conscious monkeys

Folia Pharmacologica Japonica

Volumn 124, Issue 3, 2004, Pages 153-161

  Tsukada, Hideo ^a  

^a CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Alzheimer's disease; Dementia; Donepezil; Monkey brain; PET

Indexed keywords

BENZILIC ACID DERIVATIVE; CARBON 11; CHOLINESTERASE INHIBITOR; DONEPEZIL; MUSCARINIC RECEPTOR; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; N PROPYL 3 PIPERIDYL BENZILATE; PHYSOSTIGMINE; SCOPOLAMINE; TACRINE; UNCLASSIFIED DRUG; WATER O 15;

BRAIN BLOOD FLOW; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; COGNITION; DOSE RESPONSE; MEMORY DISORDER; MICRODIALYSIS; MONKEY; NONHUMAN; OCULOMOTOR SYSTEM; PREFRONTAL CORTEX; REVIEW; SOMATOSENSORY STIMULATION; TASK PERFORMANCE; WORKING MEMORY;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANIMALS; CEREBROVASCULAR CIRCULATION; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FRONTAL LOBE; HAPLORHINI; HUMANS; INDANS; MEMORY; MICRODIALYSIS; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY;

EID: 4644245560     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.124.153     Document Type: Review

References (28)

1. Yankner BA, Davis LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 1989;245:417-420.
2. Selkoe DJ. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998;8:447-453.
3. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature. 1999;402:537-540.
4. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry. 2000;39:8698-8704.
5. Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-b peptide in mouse brain. J Neurosci. 2004;24:991-998.
6. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-βattenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
7. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Fuel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ 42 immunization. Neurology. 2003;61:46-54.
8. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[5,6-dimethoxy-1-indanon)-2-yl] -methylpiperidine hydrochloride (E2020) and related compounds. Bioorg Med Chem Lett. 1992;8:871-876.
9. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis in geriatric memory dysfunction. Science. 1982;217:408-417.
10. Perry EK. The cholinergic hypothesis - ten years on [Review]. Br Med Bull. 1986;42:63-69.
11. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease [Review]. Neuroscience. 1986;19:1-28.
12. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry. 2001;49:289-299.
13. Tsukada H, Kakiuchi T, Ando I, Shizuno H, Nakanishi S, Ouchi Y. Regulation of cerebral blood flow response to somatosensory stimulation through the cholinergic system: A PET study in unanesthetized monkey brain. Brain Res. 1997;749:10-17.
14. Tsukada H, Kakiuchi T, Ando I, Ouchi Y. Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: A PET study in unanesthetized monkeys. J Pharmacol Exp Ther. 1997;281:1408-1414.
15. Tsukada H, Sato K, Kakiuchi T, Nisbiyama S. Age-related impairment of coupling mechanism between neuronal activation and functional cerebral blood flow response was restored by cholinesterase inhibition: PET study with microdialysis in the awake monkey brain. Brain Res. 2000;857:158-164.
16. Tsukada H, Yamazaki S, Noda A, Inoue T, Matsuoka N, Kakiuchi T, et al. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, restores the regional cerebral blood flow response abolished by scopolamine but not by HA-966: a PET study with unanesthetized rhesus monkeys. Brain Res. 1999;832:118-123.
17. Cross DJ, Minoshima S, Nishimura S, Noda A, Tsukada H, Kuhl DE. Three-dimensional stereotactic surface projection (3D-SSP) analysis of macaque Brain PET: development and initial application. J Nucl Med. 2000;41:1879-1887.
18. Noda A, Takamatsu H, Minoshima S, Tsukada H, Nishimura S. Determination of kinetic rate constants for FDG and partition coefficient of water in conscious macaque and alterations in aging or anesthesia examined on parametric images with an anatomic standardization technique. J Cereb Blood Flow Metab. 2003;23:1441-1447.
19. Noda A, Takamatsu H, Matsuoka N, Koyama S, Tsukada H, Nishimura S. Effect of FK960, an antidementia drug with a novel mechanism of action, on regional cerebral blood flow and glucose metabolism in aged rhesus macaques studies with positron emission tomography. J Pharmacol Exp Ther. 2003;306:213-217.
20. 11C]methyl-3-piperidyl benzilate in the brains of conscious monkeys. Synapse. 2001;41:248-257.
21. Tsukada H, Kakiuchi T, Fukumoto D, Nishiyama S, Koga K. Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys. Brain Res. 2000;862:180-186.
22. Tsukada H, Nishiyama S, Fukumoto D, Ohba H, Sato K, Kakiuchi T. Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse. 2004;52:1-10.
23. Irie T, Fukushi K, Akiyama Y, Tamagami H, Nozaki T. Design and evaluation of radioactive analogues for mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol. 1994;21:801-808.
24. 11C]methyl-3-piperidyl benzilate in the conscious monkey brain. Synapse. 2001;40:159-169.
25. Namba H, Iyo M, Shinotoh H, Nagatsuka S, Fukushi K, Irie T. Reserved acetylcholinesterase activity in aged cerebral cortex. Lancet. 1998;351:881-882.
26. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet. 1997;349:1805-1809.
27. 11C]4-MPB. Synapse. 2001;39:182-192.
28. 2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: PET studies with microdialysis in the conscious monkey brain. J Neurosci. 2000;20:7067-7073.